Navigation Links
HPV vaccine could prevent breast cancer: Australian research
Date:9/3/2009

Vaccinating women against the human papillomavirus (HPV) may prevent some forms of breast cancer and save tens of thousands of lives each year, new Australian research suggests.

Using genetic probes, researchers at the University of New South Wales tested cancerous breast cells and found several strains of HPVs known to have a high risk of initiating cancer of the cervix. HPV has a causal role in 90-95 per cent of cervical cancers.

The research was conducted by a team from the UNSW School of Biotechnology and Biomolecular Sciences, led by Visiting Professor James Lawson, and is published in the British Journal of Cancer.

The team confirmed the presence of high-risk HPV in the nuclei of breast cancer epithelial cells in five (39 per cent) of 13 ductal carcinoma in situ and three (21 per cent) of 14 invasive ductal carcinoma (IDC) breast cancer specimens. Non-invasive or in situ cancers are those confined to the milk-making glands and do not spread to other parts of the breast or body. Invasive cancers such as IDC are more serious and account for 70-80 percent of all breast cancers.

"The finding that high risk HPV is present in a significant number of breast cancers indicates they may have a causal role in many breast cancers," says UNSW researcher, Dr Noel Whitaker, a co-author of the new report. "Confirming a cancer-causing role for HPV in some breast cancers establishes the possibility of preventing some breast cancers by vaccination against HPV," he says.

The idea that HPV has an involvement in breast cancer is controversial. Scientific reports from 15 countries around the world have identified the presence of high-risk types of HPV in breast tissue and breast cancer specimens.

But those studies have also showed widely varying results, with the prevalence of HPV-positive breast cancer in ranging from as low as four per cent to as high as 86 per cent, and have been clouded by difficulties in detecting the virus in breast specimens.

As well, the genetic probe technique used polymerase chain reaction (PCR) has been criticized for its propensity for contamination.

The technique is based on taking small genetic samples and rapidly copying them to provide a large enough sample to study.

The UNSW researchers addressed these issues by using a technique (in situ PCR) that avoids cross-contamination and that provides evidence about whether HPV genetic material is present in the nuclei of human breast cancer specimens. They validated their findings by looking for "telltale" changes linked to HPV such as enlarged nucleus surrounded by a characteristic "halo". The researchers are working on a new method that will make testing even quicker, cheaper and simpler.

Globally 1.1 million women were diagnosed with breast cancer and more than 500,000 women lost their life to the disease in 2004. Australia data reveals that 12,265 women were diagnosed with breast cancer in 2005, and 2,618 women died from breast cancer in 2006. During the past quarter century 213,658 Australian women were diagnosed with breast cancer (1982 2005) and 63,632 died from the disease (1981 2006).


'/>"/>

Contact: Dr Noel Whitaker
n.whitaker@unsw.edu.au
61-404-236-953
University of New South Wales
Source:Eurekalert

Related medicine news :

1. Pennsylvania Department of Health Launches Online H1N1 Vaccine Registry
2. Which is the Real Terminator of H1N1 Disease, the Antisepsis or the Vaccine?
3. Sinovacs H1N1 Vaccine Passes Experts Evaluation Organized by SFDA
4. IDRI to Use NanoPass Microneedle Technology for Intradermal Vaccines and Diagnostic Skin Tests
5. Sinovac Wins Beijing Public Health Bureaus Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
6. U.S. Childhood Vaccine Rates Good But Could Be Better: CDC
7. IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis
8. HPV Vaccine Could Prevent Many Penile Cancers
9. Study finds promise in combined transplant/vaccine therapy for high-risk leukemia
10. Swine Flu Vaccine Seems Safe in Early Trials
11. Cornell makes cancer vaccine for clinical use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's mental functions, ... each and every seminar, session and class she offers. At the International ... which help energize creativity, focus mental functions, enhance athletic focus and skill sets, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended ... all facets of clinical trial planning and management. Pharmica discussed the importance of ... In addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, ... expected to grow at a CAGR of 9.4% from 2017-2022 and ... at a CAGR of 9.5% from 2017 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
(Date:2/17/2017)... 2017 Arvinas LLC, a private biotechnology company ... degradation, today announced the presentation of new preclinical data ... poster session at the American Society of Clinical Oncology ... Orlando, FL. "The new ... the potential of PROTACs to drive durable and robust ...
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology: